REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
387.54
+3.10 (+0.81%)
At close: 4:00PM EST

387.54 0.00 (0.00%)
After hours: 4:05PM EST

Stock chart is not supported by your current browser
Previous Close384.44
Open384.55
Bid387.20 x 200
Ask439.00 x 300
Day's Range384.50 - 388.39
52 Week Range340.09 - 543.55
Volume367,535
Avg. Volume830,149
Market Cap41.311B
Beta1.56
PE Ratio (TTM)38.88
EPS (TTM)9.97
Earnings DateJan 31, 2018 - Feb 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est474.09
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Over the last one-month, outflows of investor capital in ETFs holding REGN totaled $1.27 billion.

  • PR Newswire7 days ago

    Regeneron Announces Upcoming Investor Conference Presentation

    TARRYTOWN, N.Y. , Nov. 15, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the 29 th Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ...

  • See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGN

  • Market Realist8 days ago

    Inside Novartis’s Ophthalmology Drugs Now

    In 3Q17, Novartis's (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

  • TheStreet.com8 days ago

    Regeneron Pharmaceuticals: Cramer's Top Takeaways

    Leonard Schleiffer, president and CEO of Regeneron Pharmaceuticals, tells Jim Cramer about drugs in his company's pipeline.

  • See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGN

  • Poor earnings updates keep European shares at seven-week low
    Reuters9 days ago

    Poor earnings updates keep European shares at seven-week low

    The pan-European STOXX 600 (.STOXX) was 0.7 percent lower at its close, with almost every sector ending in negative territory. France's EDF was the biggest faller on the day, dropping more than 10 percent after lowering its 2018 earnings and cash flow forecasts. Exane BNP Paribas affirmed its underperform rating on EDF.

  • Thomson Reuters StreetEvents12 days ago

    Edited Transcript of REGN earnings conference call or presentation 8-Nov-17 1:30pm GMT

    Q3 2017 Regeneron Pharmaceuticals Inc Earnings Call

  • Reuters12 days ago

    Novartis posts eye drug data amid play for Eylea's turf

    Novartis's (NOVN.S) bid to move in on Bayer's (BAYGn.DE) and Regeneron's (REGN.O) eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea. Active disease was observed in 23.5 percent of RTH258 patients versus 33.5 percent of Eylea patients at 16 weeks, Novartis said, of its investigational treatment for wet age-related macular degeneration (AMD), where abnormal, leaky blood vessels can cause blindness. A second, similar study found active disease in 21.9 percent of RTH258 patients versus 31.4 percent of those on Eylea for the condition affecting 20-25 million people worldwide.

  • Barrons.com13 days ago

    When Will Biotech Bounce Back?

    Biotech stocks require a good deal of faith from investors. And with third quarter earnings season coming to an end, that faith has been shaken as a string of companies, including Amgen (AMGN), Biogen ...

  • Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted
    Zacks14 days ago

    Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted

    While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.

  • Regeneron Jumps After Issuing Street-Topping Revenue, Earnings
    Investor's Business Daily14 days ago

    Regeneron Jumps After Issuing Street-Topping Revenue, Earnings

    Regeneron Pharmaceuticals reported adjusted income of $3.99 per share on $1.501 billion in sales.

  • American City Business Journals14 days ago

    Regeneron sales jump 23 percent driven by Eylea and new eczema drug

    Regeneron Pharmaceuticals is about to release a television ad campaign for one of its newest products, eczema medication Dupixent. The drug developer's total sales grew 23 percent to $1.5 billion over the past three months, propelled by sales of its Eylea medication that treats patients with macular degeneration, a leading cause of adult blindness. Eylea sales for the third quarter increased by nearly $100 million to $953.3 million compared to the same period in 2016.

  • Did Regeneron Pharmaceuticals Inc (REGN) Create Value For Shareholders?
    Simply Wall St.14 days ago

    Did Regeneron Pharmaceuticals Inc (REGN) Create Value For Shareholders?

    With an ROE of 24.06%, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) outpaced its own industry which delivered a less exciting 16.08% over the past year. Superficially, this looks great since we knowRead More...

  • Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up
    Zacks14 days ago

    Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

    Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.

  • Barrons.com14 days ago

    A Bright Spot in Blemished Biotech

    Regeneron Pharmaceuticals’s (REGN) third quarter earnings report is a bright spot in what has been a dim month for the iShares Nasdaq Biotechnology ETF (IBB). The stock popped in morning market action, lifted 2.7% to $415.42 a share by estimate-beating results. On the bottom line, Leerink’s Geoffrey Porges says there was a “surprise in operating efficiency.” Up 2.4% today to $414.19 a share, Regeneron’s stock was on fire for much of 2017, rising to a 52-week high $543.55 a share in late June on the success of the Dupixent launch.

  • Reuters14 days ago

    US STOCKS-Wall Street loses steam as banks, energy stocks weigh

    U.S. stocks stalled in late morning trading on Wednesday as weak oil prices weighed on energy stocks and doubts over a Republican tax plan and the broader outlook for U.S. growth hurt banks. Investors ...

  • Regeneron's Long-Term Issues Linger
    Bloomberg14 days ago

    Regeneron's Long-Term Issues Linger

    The uncertainty plaguing the drugmaker's stock isn't going anywhere.

  • Reuters14 days ago

    US STOCKS-Wall Street edges lower as bank stocks weigh

    Wall Street was trading slightly lower on Wednesday as bank stocks came under pressure from a near-flat Treasury yield curve and investors remained focused on the debate among lawmakers over the tax bill. Goldman Sachs was the biggest drag on the Dow while Bank of America weighed on the S&P. The S&P financial sector led the decliners, falling 0.7 percent. Senate Republican leaders are considering a one-year delay in the implementation of a major corporate tax cut to comply with Senate rules, The Washington Post reported on Tuesday, citing unidentified sources.

  • Reuters15 days ago

    US STOCKS-Wall St set to open flat with tax bill debate in focus

    Wall Street looked set to open flat on Wednesday, a day after the Dow closed at a record high for the fourth straight day, as investors keep a close tab on the debate among lawmakers on the tax bill. Shares of Snapchat operator Snap fell 11.2 percent in premarket trading after China's Tencent took a 12 percent stake. As well as slashing the corporate rate to 20 percent from 35 percent, the bill would eliminate many tax breaks and is expected to face opposition from interest groups.

  • Regeneron (REGN) Q3 Earnings Beat Estimates
    Zacks15 days ago

    Regeneron (REGN) Q3 Earnings Beat Estimates

    Regeneron (REGN) beats both earnings and sales estimates in the third quarter driven by an increase in Eylea sales.

  • Cramer’s Exec Cut: The consumer trends business leaders h...
    CNBC Videos5 days ago

    Cramer’s Exec Cut: The consumer trends business leaders h...

    Jim Cramer talked bitcoin, allergies, millennials and more to see how executives are shaping their businesses to meet the needs of modern consumers.

  • Regeneron CEO: Competitor Novartis is 'long on enthusiasm...
    CNBC Videos8 days ago

    Regeneron CEO: Competitor Novartis is 'long on enthusiasm...

    Jim Cramer caught up with Regeneron Pharmaceuticals founder, Chairman and CEO Dr. Leonard Schleifer, who pushed back against his company's rival Novartis.

  • Cramer Remix: My leftover question for GE is 'Did you mis...
    CNBC Videos8 days ago

    Cramer Remix: My leftover question for GE is 'Did you mis...

    Jim Cramer weighed in on General Electric’s decline and questioned the actions of the company’s management.

  • Regeneron President on Future of Health Care
    Bloomberg Video14 days ago

    Regeneron President on Future of Health Care

    Nov.08 -- Regeneron President and Chief Scientific Officer George D. Yancopoulos talks with Bloomberg's Joe Weisenthal at The Year Ahead Summit at Bloomberg headquarters in New York about the latest breakthroughs in health-care technology.